Johnson & Johnson Total Current Assets 2012-2026 | JNJ
Johnson & Johnson total current assets from 2012 to 2026. Total current assets can be defined as the sum of all assets that are classified as current because they will provide a benefit within one year.
- Johnson & Johnson total current assets for the quarter ending March 31, 2026 were $55.624B, a 0.48% decline year-over-year.
- Johnson & Johnson total current assets for 2025 were $55.624B, a 0.48% decline from 2024.
- Johnson & Johnson total current assets for 2024 were $55.893B, a 4.48% increase from 2023.
- Johnson & Johnson total current assets for 2023 were $53.495B, a 3.25% decline from 2022.
|
Johnson & Johnson Annual Total Current Assets (Millions of US $) |
|
|---|---|
| 2025 | $55,624 |
| 2024 | $55,893 |
| 2023 | $53,495 |
| 2022 | $55,294 |
| 2021 | $60,979 |
| 2020 | $51,237 |
| 2019 | $45,274 |
| 2018 | $46,033 |
| 2017 | $43,088 |
| 2016 | $65,032 |
| 2015 | $60,210 |
| 2014 | $55,744 |
| 2013 | $56,407 |
| 2012 | $46,116 |
| 2011 | $54,316 |
|
Johnson & Johnson Quarterly Total Current Assets (Millions of US $) |
|
|---|---|
| 2025-12-31 | $55,624 |
| 2025-09-30 | $54,611 |
| 2025-06-30 | $54,498 |
| 2025-03-31 | $71,551 |
| 2024-12-31 | $55,893 |
| 2024-09-30 | $53,249 |
| 2024-06-30 | $57,817 |
| 2024-03-31 | $57,002 |
| 2023-12-31 | $53,495 |
| 2023-09-30 | $53,703 |
| 2023-06-30 | $60,567 |
| 2023-03-31 | $64,388 |
| 2022-12-31 | $55,294 |
| 2022-09-30 | $65,236 |
| 2022-06-30 | $63,847 |
| 2022-03-31 | $60,424 |
| 2021-12-31 | $60,979 |
| 2021-09-30 | $59,889 |
| 2021-06-30 | $53,769 |
| 2021-03-31 | $52,533 |
| 2020-12-31 | $51,237 |
| 2020-09-30 | $57,578 |
| 2020-06-30 | $45,892 |
| 2020-03-31 | $44,226 |
| 2019-12-31 | $45,274 |
| 2019-09-30 | $44,333 |
| 2019-06-30 | $41,799 |
| 2019-03-31 | $41,987 |
| 2018-12-31 | $46,033 |
| 2018-09-30 | $47,194 |
| 2018-06-30 | $45,438 |
| 2018-03-31 | $42,768 |
| 2017-12-31 | $43,088 |
| 2017-09-30 | $41,829 |
| 2017-06-30 | $38,789 |
| 2017-03-31 | $63,347 |
| 2016-12-31 | $65,032 |
| 2016-09-30 | $63,319 |
| 2016-06-30 | $66,291 |
| 2016-03-31 | $62,738 |
| 2015-12-31 | $60,210 |
| 2015-09-30 | $63,494 |
| 2015-06-30 | $61,001 |
| 2015-03-31 | $58,192 |
| 2014-12-31 | $55,744 |
| 2014-09-30 | $59,973 |
| 2014-06-30 | $60,119 |
| 2014-03-31 | $57,369 |
| 2013-12-31 | $56,407 |
| 2013-09-30 | $52,176 |
| 2013-06-30 | $51,273 |
| 2013-03-31 | $47,228 |
| 2012-12-31 | $46,116 |
| 2012-09-30 | $44,791 |
| 2012-06-30 | $41,615 |
| 2012-03-31 | $57,007 |
| 2011-12-31 | $54,316 |
| 2011-09-30 | $53,443 |
| 2011-06-30 | $52,673 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $574.358B | $94.193B |
| Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |